BrainScope's device for head injury assessment was the first device in neurology cleared by FDA under the AI/Machine Learning-Enabled Medical Device category.
BrainScope has commercialized its first set of FDA cleared biomarkers for mild brain injury assessment with remarkable outcomes in major U.S. health systems, which include ~50% reduction in unnecessary head CTs and substantial reductions in patient length of stay in emergency departments.

BrainScope's FDA cleared biomarker for traumatically-induced brain bleed assessment could have applicability for assessment of other potentially life-threatening brain issues,
such as stroke or ARIA (abnormalities caused by amyloid-reducing Alzheimer's drugs).

BrainScope’s Large Neural Model Platform goes beyond the limits of traditional EEG and is being used to create new biomarkers
for other CNS indications across the spectrum of brain health and disease.

Cutting-Edge Biomarker Applications

We are dedicated to creating transformative biomarkers for a range of CNS indications, including traumatic brain injury (3 FDA-cleared biomarkers), stroke, neurodegenerative diseases, behavioral health, and neuroinflammatory disorders, with applicability across:

Early Detection

Identifying brain dysfunction at its earliest stages for more timely intervention. We can also use EEG captured  by third-party devices.

Tell The Reader More

Providing an objective, data-driven approach to evaluate disease progression.

Monitoring Treatment Effects

Helping determine efficacy of therapeutics and identifying potentially dangerous side effects such as ARIA associated with anti-amyloid Alzheimer's drugs.

Digital Neural Twinning and Outcome Prediction

Enabling informed decision-making and patient selection.

Subtyping Disease

Recognizing that there may be more than one form of a disease, and that treatment and treatment response may vary by subtype.